ReviewNeuro-oncology advances
Systematic review and meta-analysis of breast cancer brain metastasis and primary tumor receptor expression discordance.
Review in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Systematic review of the management of brain metastases from hormone receptor positive breast cancer.Journal of neuro-oncology · 2023Pooled it
- Clinical Implementation and Oncological Relevance of Molecular Profiling in Brain Metastases Patients-A Multicenter Retrospective Cohort Study.International journal of cancer · 2026Article
- Saliency-Curated Deep Learning for Predicting Receptor Status in Breast Cancer Brain Metastases.Journal of clinical medicine · 2026Article
- Clinical and molecular features of resected breast cancer brain metastases: a single center retrospective cohort study.Breast cancer research and treatment · 2026Article
- Pituitary metastasis as an endocrine-neuro-ophthalmologic emergency: clinical red flags and outcomes from a contemporary tertiary-center series.Pituitary · 2026Article
- Article
- HER2 heterogeneity between primary cancers and brain metastases: a retrospective analysis of 185 matched pairs across multiple cancer types.Journal of neuro-oncology · 2026Article
- Stereotactic radiotherapy for brain metastases: indications, dose fractionation, technological innovations, and evolving combination strategies - a comprehensive review.Frontiers in oncology · 2026Review
- Ki-67 correlations in breast cancer.Journal of medicine and life · 2025Article
- Clinical applications of next-generation sequencing-based ctDNA analyses in breast cancer: defining treatment targets and dynamic changes during disease progression.Molecular oncology · 2025Review
- Genomic and immune profiling of breast cancer brain metastases.Acta neuropathologica communications · 2025Article
- A new, immunocompetent brain-metastatic mouse model of HER2-positive breast cancer.Clinical & experimental metastasis · 2025Article
- Analysis of HER2 expression changes from breast primary to brain metastases and the impact of HER2-low expression on overall survival.Neuro-oncology · 2025Article
- Beyond Primary HER2 Expression: Trastuzumab Deruxtecan's Efficacy in Brain Metastasis.Cancers · 2024Article
- Tamoxifen metabolites treatment promotes ERα+ transition to triple negative phenotype in vitro, effects of LDL in chemoresistance.Bioscience reports · 2024Article
- Stereotactic Radiosurgery for Women Older than 65 with Breast Cancer Brain Metastases.Cancers · 2023Article
- Incidence of HER2-expressing brain metastases in patients with HER2-null breast cancer: a matched case analysis.NPJ breast cancer · 2023Article
- A Case ofWorld journal of oncology · 2023Article
- Molecular signaling network and therapeutic developments in breast cancer brain metastasis.Advances in cancer biology - metastasis · 2023Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChange in hormone receptor (estrogen [ER] and progesterone [PR]) and/or human epidermal growth factor receptor type 2 (HER2) status during the evolutionary course of metastatic breast cancer and the effect of tumor classification subtype switching remain understudied and underappreciated in brain metastasis patients.
methodsUsing preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines, a systematic review of series published prior to April 2020 obtained from the Medline database of biopsied or resected breast cancer brain metastasis (BCBM) was performed. Weighted random effects models were used to calculate pooled estimates.
results15 full-text articles were included with receptor expression analyses on 1373 patients who underwent biopsy or resection of at least one intracranial lesion to compare to the primary tumor. Primary tumor receptor expression immunophenotypes were 45.0% ER+, 41.0% ER-, 31.0% PR+, 51.0% PR-, 35% HER2+, and 47.0% HER2-. Corresponding BCBM immunophenotypes were 19.0% ER+, 31.0% ER-, 13.0% PR+, 40.0% PR-, 21.0% HER2+, and 26.0% HER2-. On primary/BCBM comparison, 540 patients (42.6%) exhibited discordance in any receptor with 17.0% (95% CI: 13.0%-23.0%) discordant on ER, 23.0% (95% CI: 18.0%-30.0%) discordant on PR, and 12.0% (95% CI: 8.0%-16.0%) discordant on HER2 status. The most common receptor conversions found in BCBM were ER loss 11.0% (95% CI: 8.0%-16.0%), PR loss 15.0% (95% CI: 11.0%-21.0%), and HER2 gain 9.0% (95% CI: 7.0%-11.0%).
conclusionsBCBM exhibits significant receptor expression discordance in comparison to primary tumors in approximately 40% of patients. Classification patterns need to be analyzed to determine factors predictive of BCBM/primary tumor discordance. Overall, tumor subtype switching and its effect on clinical management remains underappreciated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.